DeepMed Research

United Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $15.5B

Website: http://www.unither.com

Clinical Trials

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Phase 2

Terminated

Conditions: Primary Refractory Neuroblastoma

Interventions: Biological: MAb-3F8
Biological: Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Biological: 13-cis-Retinoic Acid

First Posted Date: 2009-09-01

Last Posted Date: 2013-03-08

Lead Sponsor: United Therapeutics

Target Recruit Count: 1

Registration Number: NCT00969722

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Children's Hospital at Montefiore, Bronx, New York, United States

and more 12 locations

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Phase 1

Completed

Conditions: Hypertension, Pulmonary
Pulmonary Arterial Hypertension

First Posted Date: 2009-08-20

Last Posted Date: 2010-03-08

Lead Sponsor: United Therapeutics

Target Recruit Count: 30

Registration Number: NCT00963027

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Phase 1

Completed

Conditions: Hypertension, Pulmonary
Pulmonary Arterial Hypertension

First Posted Date: 2009-08-20

Last Posted Date: 2010-03-08

Lead Sponsor: United Therapeutics

Target Recruit Count: 32

Registration Number: NCT00963001

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

Phase 3

Completed

Conditions: Pulmonary Hypertension

Interventions: Drug: Placebo
Drug: UT-15C SR

First Posted Date: 2009-04-24

Last Posted Date: 2013-01-15

Lead Sponsor: United Therapeutics

Target Recruit Count: 310

Registration Number: NCT00887978

Locations: 🇺🇸
Washington University Hospital, St. Louis, Missouri, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States

and more 59 locations

Open-Label Study of Oral Treprostinil in Digital Ulcers

Phase 2

Terminated

Conditions: Systemic Sclerosis

Interventions: Drug: treprostinil diethanolamine

First Posted Date: 2009-02-20

Last Posted Date: 2024-06-18

Lead Sponsor: United Therapeutics

Target Recruit Count: 115

Registration Number: NCT00848107

Locations: 🇺🇸
Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Boston University School of Medicine, Boston, Massachusetts, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 23 locations

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

Phase 1

Completed

Conditions: Systemic Sclerosis

Interventions: Drug: treprostinil diethanolamine

First Posted Date: 2009-02-20

Last Posted Date: 2012-10-23

Lead Sponsor: United Therapeutics

Target Recruit Count: 28

Registration Number: NCT00848939

Locations: 🇺🇸
Johns Hopkins Scleroderma Center, Baltimore, Maryland, United States
🇺🇸
University of Michigan Scleroderma Program, Ann Arbor, Michigan, United States
🇺🇸
Boston University School of Medicine Rheumatology Arthritis Center, Boston, Massachusetts, United States

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Phase 2

Completed

Conditions: Scleroderma
Systemic Sclerosis

Interventions: Drug: treprostinil diethanolamine
Drug: placebo

First Posted Date: 2008-10-20

Last Posted Date: 2023-12-28

Lead Sponsor: United Therapeutics

Target Recruit Count: 148

Registration Number: NCT00775463

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Indiana School of Medicine, Indianapolis, Indiana, United States
🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

and more 27 locations

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Phase 3

Withdrawn

Conditions: Pulmonary Hypertension

Interventions: Drug: Placebo
Drug: UT-15C 0.25 mg
Drug: UT-15C 1 mg
Drug: UT-15C 5 mg

First Posted Date: 2008-09-26

Last Posted Date: 2013-01-30

Lead Sponsor: United Therapeutics

Registration Number: NCT00760916

Locations: 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇲🇽
Unidad de Investigacion Clinica en Medicina (UDICEM), Monterrey, Mexico

and more 28 locations

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Phase 4

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Inhaled treprostinil

First Posted Date: 2008-08-26

Last Posted Date: 2013-02-20

Lead Sponsor: United Therapeutics

Target Recruit Count: 73

Registration Number: NCT00741819

Locations: 🇺🇸
Cornell University Medical Center, New York City, New York, United States
🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States

and more 12 locations

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Phase 4

Terminated

Conditions: Hypertension, Pulmonary

Interventions: Drug: treprostinil sodium

First Posted Date: 2008-03-26

Last Posted Date: 2024-01-03

Lead Sponsor: United Therapeutics

Target Recruit Count: 7

Registration Number: NCT00643604

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy